Biochemical and structural investigations on phosphoribosylpyrophosphate synthetase from Mycobacterium smegmatis

PLoS One. 2017 Apr 18;12(4):e0175815. doi: 10.1371/journal.pone.0175815. eCollection 2017.

Abstract

Mycobacterium smegmatis represents one model for studying the biology of its pathogenic relative Mycobacterium tuberculosis. The structural characterization of a M. tuberculosis ortholog protein can serve as a valid tool for the development of molecules active against the M. tuberculosis target. In this context, we report the biochemical and structural characterization of M. smegmatis phosphoribosylpyrophosphate synthetase (PrsA), the ortholog of M. tuberculosis PrsA, the unique enzyme responsible for the synthesis of phosphoribosylpyrophosphate (PRPP). PRPP is a key metabolite involved in several biosynthetic pathways including those for histidine, tryptophan, nucleotides and decaprenylphosphoryl-arabinose, an essential precursor for the mycobacterial cell wall biosynthesis. Since M. tuberculosis PrsA has been validated as a drug target for the development of antitubercular agents, the data presented here will add to the knowledge of the mycobacterial enzyme and could contribute to the development of M. tuberculosis PrsA inhibitors of potential pharmacological interest.

MeSH terms

  • Amino Acid Sequence
  • Anti-Bacterial Agents / pharmacology
  • Catalytic Domain
  • Crystallography, X-Ray
  • Drug Discovery
  • Humans
  • Models, Molecular
  • Molecular Targeted Therapy
  • Mycobacterium Infections, Nontuberculous / drug therapy
  • Mycobacterium Infections, Nontuberculous / microbiology*
  • Mycobacterium smegmatis / chemistry
  • Mycobacterium smegmatis / drug effects
  • Mycobacterium smegmatis / enzymology*
  • Mycobacterium smegmatis / metabolism
  • Protein Conformation
  • Ribose-Phosphate Pyrophosphokinase / chemistry*
  • Ribose-Phosphate Pyrophosphokinase / metabolism*
  • Sequence Alignment
  • Substrate Specificity

Substances

  • Anti-Bacterial Agents
  • Ribose-Phosphate Pyrophosphokinase

Grants and funding

This work was funded by the European Community’s Seventh Framework Program (Grant 260872; MM4TB) and the Research Program on Emerging and Re-emerging Infectious Diseases from Japan Agency for Medical Research and Development, AMED. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.